Glenmark Pharma Shares Surge 5%: Why Glenmark Stock is Rising Today

Market Data: 29 Sep 2026 • 03:10 PM IST
Status: Automated market-move research draft
GLENMARK PHARMACEUTICALS
GLENMARK • NSE • F&O Stock
+4.98%

GLENMARK PHARMACEUTICALS traded at ₹2,441.50, +4.98% versus the previous close of ₹2,325.70. Latest market data: 29 Sep 2026 • 03:10 PM IST.

Key Takeaways
  • The stock is +4.98% at ₹2,441.50.
  • Likely reason: Strong volume-backed buying and sector outperformance
  • Approximate traded value is ₹307.19 crore.
  • It is -3.79% from its 52-week high and +36.20% from its 52-week low.
  • The stock is being compared with Nifty Pharma alongside the Nifty 50.

GLENMARK PHARMACEUTICALS Share Price Today – Market Snapshot

Symbol
GLENMARK
Date & Time
29 Sep 2026 • 03:10 PM IST
Change
+4.98%
Previous Close
₹2,325.70
Open
₹2,342.20
Day High
₹2,441.50
Day Low
₹2,292.10
Price / Close
₹2,441.50
Volume
1,258,203
52-Week Range
₹1,792.60 – ₹2,537.60

Why Is GLENMARK PHARMACEUTICALS Share Price Rising Today?

Glenmark Pharmaceuticals shares surged 4.98% to close at ₹2,441.50 today, trading aggressively near the upper end of its intraday range between ₹2,292.10 and ₹2,441.50. Market participation was exceptionally strong, with trading volume clocking over 2.5 times its 20-day average and delivery quantity scaling up to 65.75%, signalling heavy institutional or delivery-based accumulation.

The stock notably outperformed the broader market and its sectoral peers. While the benchmark Nifty dipped 0.28%, the Nifty Pharma sector index posted a modest 0.64% gain, making Glenmark's sharp upward trajectory one of the standout movers in the pharmaceutical space.

While no single headline-grabbing catalyst dropped today, the stock's robust momentum coincides with a series of positive regulatory and operational updates over the past weeks, including the U.S. FDA's VAI classification and Establishment Inspection Report (EIR) for its Goa facility, alongside the global expansion of its respiratory footprint with the Ryaltris launch in Brazil.

Likely Reason for Today’s Move

medium confidence

Strong volume-backed buying and sector outperformance
Glenmark rallied sharply by nearly 5% accompanied by massive volume expansion (2.5x of 20-day average) and high delivery percentage, outpacing the broader pharmaceutical index. The move appears supported by recent positive regulatory developments like the U.S. FDA clearance for the Goa plant and institutional accumulation.
  • Daily return of +4.98% with heavy volumes at 2.57x the 20-day average
  • High delivery percentage of 65.75% indicating strong institutional interest
  • Outperformance against Nifty (-0.28%) and Nifty Pharma (+0.64%)
Understand the Move Beyond the Headline
Explore WittyTrades research across price action, volume, derivatives, company developments and market context.

Explore Research Plans

Performance Context

TODAY
+4.98%
5 DAYS
-0.81%
20 DAYS
-1.17%
VS 52W HIGH
-3.79%
FROM 52W LOW
+36.20%

Cash-Market Activity

Latest NSE EOD report: 2026-09-29
Today’s Volume 1,258,203
5-Day Avg. Volume 817,296
20-Day Avg. Volume 488,980
Volume vs 20-Day Avg. 2.57x
Delivery Quantity 839,781
Delivery % 65.75%
Number of Trades 56,808

Derivative-Market Activity

NSE F&O EOD report: 2026-09-28 • Expiry: 2026-09-29
Near-Month Futures ₹2,316.30
Cash Reference ₹2,325.75
Premium / Discount ₹-9.45 (-0.41%)
Change in Premium ₹-3.85
Futures Volume 8,501
Volume vs Previous Session 0.77x
Open Interest 1,012,875
OI vs Previous Session 0.27x

Recent Brokerage Views

Brokerage
Motilal Oswal

View
Buy

Target
₹2,570

Date
31 Aug 2026

Key rationale / reported context: Recommended as a stock pick by analyst Chandan Taparia, backed by favorable technical setups and structural business momentum.

Brokerage views are third-party opinions and are not WittyTrades recommendations.

WittyTrades Data Insight

Price Position: The stock is near the upper end of the day’s trading range.

Move From Open: +4.24%.

Intraday Range: 6.42% of the previous close.

5-Day Performance: -0.81%; 20-Day Performance: -1.17%.

Beyond Charts — Research Backed by Data
Move from market news to structured research using price action, market context, volume behaviour and multiple research inputs.

View Research Segments

Latest Company Developments

US FDA issues EIR with VAI for Goa facility
23-Sep-2026
Glenmark Pharmaceuticals announced the receipt of the Establishment Inspection Report (EIR) from the U.S. FDA for its manufacturing facility located in Goa. The inspection concluded with a Voluntary Action Indicated (VAI) classification, indicating satisfactory regulatory compliance.
Why it matters: A VAI classification removes key regulatory overhangs for the Goa plant, securing export visibility and smooth operations for key regulated markets.

Global respiratory expansion with Ryaltris launch in Brazil
11-Sep-2026
The company expanded its international specialty footprint by launching its flagship respiratory product, Ryaltris, in Brazil. This commercial rollout strengthens the company's branded respiratory portfolio in key emerging international regions.
Why it matters: Commercializing high-margin specialty products in large international markets drives revenue diversification and supports medium-term margin expansion.

Launch of Calcium Gluconate Injection in the USA
21-Aug-2026
Glenmark Pharmaceuticals Inc., USA, announced the commercial launch of Calcium Gluconate Injection USP in various dosage formats, including single-dose vials and pharmacy bulk packages. This portfolio addition strengthens the company's institutional injectables segment in North America.
Why it matters: Expands the complex generics portfolio in the highly lucrative US market, supporting steady revenue generation.

Relative Performance

GLENMARK PHARMACEUTICALS +4.98%
Nifty 50 -0.28%
Nifty Pharma +0.64%
Vs Nifty 50 +5.26%
Vs Sector +4.34%

Technical Context

Price ₹2,441.50
Day High / Low ₹2,441.50 / ₹2,292.10
52-Week High ₹2,537.60
52-Week Low ₹1,792.60
5-Day Return -0.81%
20-Day Return -1.17%

What Should Traders and Investors Watch Next?

  • Sustained delivery volume trends and open interest adjustments in the near term
  • Execution of newly launched products in the US and Latin American markets
  • Regulatory updates regarding other manufacturing plants and pending approvals
  • Price action relative to the 52-week high of ₹2,537.60
Get Research-Backed Market Opportunities
Explore WittyTrades research segments for trading, swing and investment ideas.

Get Research-Backed Recommendations

Catalyst note: There is no single same-day trigger announced today, but the sharp rally is backed by heavy volume accumulation and sustained positive operational catalysts.

Frequently Asked Questions

What is the likely reason for today’s move?

Glenmark rallied sharply by nearly 5% accompanied by massive volume expansion (2.5x of 20-day average) and high delivery percentage, outpacing the broader pharmaceutical index. The move appears supported by recent positive regulatory developments like the U.S. FDA clearance for the Goa plant and institutional accumulation.

Is trading volume elevated?

Today’s volume is 1,258,203. The latest 20-day average available is 488,980, equivalent to about 2.57x of the recent average.

What does the derivatives market show?

The latest official NSE F&O report is summarised in the Derivative-Market Activity box above.

Before acting on this stock

Consult your own investment adviser before acting on any security. If you are interested in stock research or other available research categories, review the WittyTrades subscription plans and research segments.

Source & methodology:
Market data, exchange filings, company disclosures and reputable business-media reports are collected automatically and summarised for investor context. Material facts are cross-checked where possible; price data may be delayed and a cited development should not be assumed to be the sole cause of a market move unless the evidence supports that conclusion.

Article by: WittyTrades Research Desk

Disclaimer:
Investments in securities markets are subject to market risks. Read all related documents carefully before investing.
Registration granted by SEBI, membership of a supervisory body and certification from NISM do not guarantee performance of the intermediary or provide any assurance of returns to investors.
This article is intended for informational and educational purposes and should not be treated as personalised investment advice or a recommendation to buy, sell or hold any security.
Market data may be delayed and readers should independently verify current prices and disclosures before taking investment decisions.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top